Pharmaceutical contract manufacturing firms now leverage AI to optimize production efficiency. A new report from GlobeNewswire highlights this shift alongside a trend toward complex biologics outsourcing. These tools streamline operations for CDMOs seeking specialized production scales. The impact remains incremental, focusing on operational cost reductions rather than new drug discovery.